Next-generation contract research organization (CRO) Ginkgo Bioworks is quietly building momentum among three core customer groups. If the trend continues to hold, then these industries could provide a foundation to build upon during the company’s turnaround.

In the first quarter of 2021, customers hailing from biopharma, agriculture, and government (BAG) combined for 33% of Cell Engineering revenue. That slipped to a low of 15% in the final three months of 2021.

But the business has steadily increased its focus on these three customer groups in the three years since. By the second quarter of 2024, BAG customers accounted for 70% of Cell Engineering revenue for Ginkgo Bioworks. This core group hasn’t accounted for less than 40% of the segment’s revenue since the second quarter of 2022.